Sodium-glucose cotransporter 2 (SGLT2) inhibitors consistently reduce cardiovascular mortality and heart failure hospitalizations in patients with type 2 diabetes and heart failure.
Do specific glucose-lowering medications improve cardiovascular outcomes in patients with type 2 diabetes and heart failure?
The choice of glucose-lowering agents in patients with T2DM and HF is critical, as certain classes like SGLT2 inhibitors offer cardiovascular benefits while others like thiazolidinediones can exacerbate heart failure.
Diabetes and heart failure (HF) are common diseases, each affecting large segments of the world population. Moreover, prevalence rates for both are expected to rise dramatically over coming decades. The high prevalence rates of both diseases and wellrecognized association of diabetes as a risk factor for HF make it inevitable that both diseases co-exist in a large number of patients, complicating their management and increasing the risk of a poor outcome. Management of diabetes has been shown to impact clinical events in patients with HF and there is emerging evidence that agents used to treat diabetes can reduce HF events, even in non-diabetic patients. In this review we summarize the clinical course and treatment of patients with type 2 diabetes mellitus (T2DM) and HF and review the efficacy and safety of pharmacological agents in patients with T2DM at risk for HF and those with established disease.
Shen et al. (Thu,) conducted a review in Type 2 diabetes mellitus and heart failure. Glucose-lowering medications (SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors) was evaluated. Sodium-glucose cotransporter 2 (SGLT2) inhibitors consistently reduce cardiovascular mortality and heart failure hospitalizations in patients with type 2 diabetes and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: